Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
Novamind commences formal trading on the OTCQB under the symbol "NVMDF".
Field Trip will focus on Treatment-Resistant Depression and Postpartum Depression as indications for drug development of FT-104.
Psyched Wellness moves a step closer to commencing its Phase I clinical trial on AME-1. The company is still targeting commercialization for 2022.
Red Light Holland closes on its majority ownership in Acadian Exotic Mushrooms, now holding a 51% interest.
Mydecine and Johns Hopkins plan a "seamless" (combined) Phase II/III clinical trial of MYCO-001 to treat nicotine addiction.
MINDCURE reports a net loss for the fiscal year of CAD$10.2 million as it prepares to deploy its iSTRYM digital therapeutics platform. Cash and equivalents of CAD$18.3 million.
Red Light Holland reports its Q1 for fiscal year 2022. The company also confirms closing on its acquisition of Mera Life Sciences.
MINDCURE has released the initial version of its iSTRYM digital therapeutics platform and expects to begin full commercial deployment in Q1 of 2022.
MindMed and Forian will collaborate on drug R&D via the real-world evidence (RWE) pathway to drug development.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now